A Dual Immunosensor Based on Optical Weak Value Amplification for Simultaneous Detection of CA125 and HE4

Bei Wang, Gengyu Liang, Lingqin Meng, Han Li, Zishuo Song, Xu Yang, Yonghong He, Dengle Duan, Qiaocui Shi, Tian Guan, Gong YaSensors 2025 · DOI

TL;DR

This paper presents a novel dual immunosensor that simultaneously detects two key ovarian cancer biomarkers, CA125 and HE4, with high precision and sensitivity. By leveraging optical weak value amplification (WVA) and an oriented antibody immobilization strategy, the sensor offers a label-free, real-time, and cost-effective approach for early cancer screening and diagnosis.

What Problem Does This Paper Address?

Early detection of cancer is crucial for improving patient outcomes. While individual biomarkers exist, their specificity and sensitivity can be limited. For ovarian cancer, combining CA125 and HE4 has shown the most promise for effective screening. However, existing detection methods often rely on complex amplification techniques, require labels, or are not real-time. This creates a need for a simpler, more sensitive, and simultaneous detection method for these critical biomarkers.

Methods

The core of this work is a dual immunosensor that combines two key technologies:

  • Optical Weak Value Amplification (WVA): This technique amplifies tiny optical phase shifts caused by molecular interactions. In this setup, light is passed through a prism, and the refractive index change at the prism's surface (due to antigen-antibody binding) creates a small phase difference between polarized light components. WVA amplifies this phase difference, converting it into a measurable intensity change. This allows for highly sensitive detection without the need for traditional fluorescent or colorimetric labels.
  • Oriented Antibody Immobilization: To ensure optimal antigen binding, the researchers employed recombinant protein G. Protein G specifically binds to the Fc region of antibodies, orienting them on the sensor surface with their antigen-binding sites (Fab regions) exposed. This strategy, compared to random immobilization, significantly increased the number of functional antibody binding sites, leading to improved sensor performance.
  • Self-Assembled Monolayer (SAM) Functionalization: Dopamine was used to create a polydopamine layer on the prism surface, which then served as a platform for immobilizing protein G and subsequently the antibodies.
  • Self-Reference Differential Calibration: To mitigate environmental noise (like temperature fluctuations), the system uses a differential approach. Signals from a measurement channel (where the sample is) and a reference channel (with a buffer) are compared, and the difference is analyzed. This significantly reduces background interference.

Datasets

The study did not use pre-existing datasets for training. Instead, it relied on experimental data generated by the developed immunosensor. The evaluation involved testing with known concentrations of CA125 and HE4 antigens, as well as interfering proteins (AFP and CEA) to assess selectivity.

Key Insights and Ideas

  • WVA as a Powerful Label-Free Amplification Tool: The study demonstrates that WVA can effectively amplify subtle refractive index changes, making it a highly sensitive platform for biosensing without the need for labels. This simplifies the assay and reduces potential interference from labeling molecules.
  • Oriented Immobilization is Key for Performance: The use of protein G for oriented antibody immobilization proved crucial. It not only increased the density of functional antibodies but also ensured their optimal orientation, leading to a significant improvement in binding site availability and overall sensor efficiency.
  • Simultaneous Detection is Achievable and Beneficial: The successful simultaneous detection of two distinct biomarkers (CA125 and HE4) in a single assay highlights the potential for developing multi-analyte biosensors for complex diagnostic scenarios.
  • Self-Reference Calibration Enhances Robustness: The differential calibration method effectively filters out environmental noise, making the sensor more reliable for real-world applications where stable conditions might not always be guaranteed.

Key Results

  • High Sensitivity and Low Detection Limits: The immunosensor achieved detection limits of 5.39 U/mL for CA125 and 1.79 ng/mL for HE4, which meet clinical diagnostic requirements.
  • Excellent Specificity: The sensor demonstrated high selectivity, accurately distinguishing CA125 and HE4 from interfering proteins like AFP and CEA, even at concentrations significantly above clinical thresholds.
  • Improved Antibody Immobilization: The oriented immobilization strategy using protein G resulted in a 2.27-fold increase in antibody immobilization and 1.59 times more binding sites compared to random immobilization.
  • Real-Time Detection: The WVA system allows for real-time monitoring of antigen-antibody binding events.
  • Label-Free Operation: The sensor does not require any fluorescent or colorimetric labels, simplifying the assay procedure and reducing costs.

Limitations and Future Work

  • Limited to Two Biomarkers: While the study successfully demonstrated dual detection, the current setup is limited to two analytes.
  • Complex Sample Matrix: While selectivity was tested with AFP and CEA, the performance in a full serum matrix with a wider range of potential interferents was not extensively detailed.
  • Future Directions: The authors propose extending this approach to detect a broader range of biomarkers for different tumor systems by optimizing the optical system and sensor channel structure. Further investigation into complex biological matrices is also implied.

Summary updated

Abstract

Simultaneous detection of multiple biomarkers is essential for effective cancer screening. Taking ovarian cancer as an example, the combined detection of CA125 and HE4 has proven to be the most efficient and accurate among multiple biomarker combinations. In this study, we proposed a dual immunosensor based on weak value amplification (WVA) to detect ovarian cancer. By modifying the sensor surface through a self-assembled monolayer technique and utilizing recombinant protein G for antibody enrichment and directional capture, the sensor enables high-precision, simultaneous detection of CA125 and HE4, with detection limits of 5.39 U/mL and 1.79 ng/mL, respectively. Furthermore, the sensor demonstrates excellent specificity, effectively distinguishing target analytes from non-target molecules. This study provides a novel approach for early cancer screening and clinical diagnosis, highlighting the potential of WVA-based immunosensors in ovarian cancer detection.
BibTeX
@inproceedings{wang2025dual,
  author = {Bei Wang and Gengyu Liang and Lingqin Meng and Han Li and Zishuo Song and Xu Yang and Yonghong He and Dengle Duan and Qiaocui SHI and Tian Guan and Gong Ya},
  title = {{A Dual Immunosensor Based on Optical Weak Value Amplification for Simultaneous Detection of CA125 and HE4}},
  booktitle = {Sensors},
  year = {2025},
  doi = {10.3390/s25113347},
}
Figure